Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 18/20 | 0.81 |
| ▸ | MMP13 | P45452 | 14/20 | 0.68 |
| ▸ | MMP1 | P03956 | 13/20 | 0.68 |
| ▸ | MMP9 | P14780 | 13/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6262928 | 0.91 | ADAM17 (0.81) | ADAM17MMP13MMP1MMP9CYP1A2 | |
| SCHEMBL4026606 | 0.91 | ADAM17 (0.82) | ADAM17MMP13MMP1MMP9 | |
| Hydroxyamine SCHEMBL6702004 | 0.90 | ADAM17 (0.82) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL6275563 | 0.90 | ADAM17 (0.85) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL4027101 | 0.89 | ADAM17 (1.00) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL6704851 | 0.88 | ADAM17 (0.80) | ADAM17MMP13MMP1MMP9CYP1A2 | |
| SCHEMBL4033569 | 0.88 | ADAM17 (0.82) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL4033702 | 0.85 | ADAM17 (0.60) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL6262677 | 0.84 | ADAM17 (0.79) | ADAM17MMP13MMP1MMP9CYP1A2 | |
| SCHEMBL6864846 | 0.84 | ADAM17 (0.79) | ADAM17MMP13MMP1MMP9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | PKD1, PKD2, PCSK6 | ADAM17 9/4885MMP13 246/4885MMP1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.